SCHEMBL3920649

SCHEMBL3920649

COc1cc2c(Oc3ccc(NC(=O)c4cccn(C)c4=O)cc3F)ccnc2cc1OCCCN1CCOCC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 18/20 0.72
FLT3 P36888 3/20 0.72
INSR P06213 2/20 0.71
AXL P30530 3/20 0.70
KDR P35968 2/20 0.69
PLK4 O00444 1/20 0.69
STK25 O00506 1/20 0.69
CIT O14578 1/20 0.69
AURKA O14965 1/20 0.69
CHUK O15111 1/20 0.69
MUSK O15146 1/20 0.69
EPHB6 O15197 1/20 0.69
MAPK13 O15264 1/20 0.69
MAP3K13 O43283 1/20 0.69
DAPK3 O43293 1/20 0.69
MAP3K7 O43318 1/20 0.69
RIPK2 O43353 1/20 0.69
JAK2 O60674 1/20 0.69
ROCK2 O75116 1/20 0.69
PAK3 O75914 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3913545 0.91 MET (0.77) METFLT3INSRAXLKDR
SCHEMBL6520309 0.91 MET (0.72) METFLT3INSRAXLKDR
SCHEMBL3912896 0.91 MET (0.70) METFLT3INSRAXLKDR
SCHEMBL3987180 0.90 MET (0.69) METFLT3INSRAXLKDR
SCHEMBL3916355 0.89 MET (0.67) METFLT3INSRAXLKDR
SCHEMBL6523334 0.89 MET (0.75) METFLT3INSRAXLKDR
SCHEMBL3911887 0.87 MET (0.75) METFLT3INSRAXLKDR
SCHEMBL3913798 0.87 MET (0.76) METFLT3INSRAXLKDR
SCHEMBL168022 0.86 MET (0.74) METFLT3INSRAXLKDR
SCHEMBL30716533 0.85 MET (0.76) METFLT3INSRKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE GAUDINO JOHN 2011-03-03 US claimed
EP-2032538-A2 QUINOLINE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2009-03-11 EP claimed
WO-2007146824-A2 QUINOLINE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-12-21 WO claimed
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE GAUDINO JOHN 2011-03-03 US disclosed
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE GAUDINO JOHN 2011-03-03 US disclosed
EP-2032538-A2 QUINOLINE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2009-03-11 EP disclosed
WO-2007146824-A2 QUINOLINE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-12-21 WO disclosed
WO-2007146824-A2 QUINOLINE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE TK1, ABL1, ROR1 MET 563/4885FLT3 49/4885INSR 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.